Supreme Court won't review CAFC ruling on Lilly's Zyprexa

Gannett News stated that the US Supreme Court declined to hear an appeal by generics on Lilly's Zyprexa:

Zenith Goldline Pharmaceuticals, Dr. Reddy's Laboratories and Teva Pharmaceutical Industries had argued that Lilly's patent was no longer valid because discovery of Zyprexa's molecular structure was covered by a previous Lilly patent.

Separately:

Several states are suing Lilly, claiming it marketed Zyprexa for off-label uses, including treatment of dementia, depression and autism, without warning about its risks.

Also

http://ipbiz.blogspot.com/2006/12/lillys-zyprexa-patent-upheld-at-cafc.html